Clinical Trial Update: Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy [Phase 2]

View source ↗

Summary

A Phase 2 pilot study of Acthar Gel for chronic inflammatory demyelinating polyneuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Acthar Gel (repository corticotropin injection)

Snippet

Sponsor: Mamatha Pasnoor, MD | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Status: WITHDRAWN